Current treatment strategies for high-stage melanoma are based around the use of immunotherapy with immune checkpoint inhibitors such as anti-PDL1 or anti-CTLA4 antibodies to stimulate anti-cancer T cell responses, or signal-transduction inhibitors such as those targeting BRAF and MEK pathways [3, 4]. The gene discussed is CTLA4; the disease is cancer.